2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Omics Technologies, Serologic Tests, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Transfusion, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Hematopoiesis, Immune Mechanism, Metabolism, Clinical Practice (Health Services and Quality), Diseases, Genetic Disorders, Immunology, Autoimmune Disorders, Immunodeficiency, Lymphoid Malignancies, Plasma Cell Disorders, Metabolic Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

4746 Defining the idiopathic plasmacytic lymphadenopathy subtype of idiopathic multicentric castleman disease: Chinese criteria vs. kojima criteria

Yu-han Gao, PhD, Siyuan Li2, Yue Dang3, Haoyi Xu4, Hong-yi Wang5, Zihan Yang, MD6, Hong-Xiao Han, MD7, Lu Zhang, M.D.8, Jian Li, MD9
1 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
3 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
4 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
6 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
7 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
8 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
9 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Background

Idiopathic plasmacytic lymphadenopathy (IPL) is recognized as a distinct subtype of idiopathic multicentric Castleman disease (iMCD), characterized by a prominent inflammatory state but a favourable prognosis. However, a global consensus on the diagnostic criteria for iMCD-IPL remains unestablished. Current research in the iMCD field utilizes varying definitions of IPL, such as the Japanese Kojima criteria (2009) and the criteria adopted in the Chinese Guidelines for Castleman Disease (2025 version). Compared to the Kojima criteria, the Chinese IPL criteria relax the restriction on serum IgG concentration and introduce thrombocytosis (elevated platelet count, PLT) as an indicator. This study aims to compare the differences between the Chinese and Kojima criteria in defining iMCD-IPL, with the goal of further optimizing the definition of the IPL subtype.

Methods

This single-centre, retrospective study analyzed non-TAFRO iMCD patients with available baseline IgG and complete blood count data, admitted to Peking Union Medical College Hospital (PUMCH) between January 2010 and May 2026. Patients were stratified into IPLc/NOSc groups (c = Chinese criteria) and IPLk/NOSk groups (k = Kojima criteria) according to the Chinese Guidelines for Diagnosis and Treatment of Castleman Disease (2025) and the Japanese Kojima criteria, respectively. Kaplan-Meier survival curves were plotted to compare prognostic differences. A Cox proportional hazards regression model was utilized to analyze the interaction and confounding factors for predictors of overall survival (OS).

Results

A total of 488 non-TAFRO iMCD patients were enrolled. Based on the Chinese criteria, 182 patients (37.3%) were classified as IPLc, while 180 patients (36.9%) were classified as IPLk according to the Kojima criteria, indicating a similar proportion of identified IPL patients between the two methods. Overall, 109 patients met both criteria, 73 met only the Chinese criteria, 71 met only the Kojima criteria, and 235 met neither. During a median follow-up of 55.7 months, 28 deaths (5.7%) were recorded. Survival analysis demonstrated that IPL patients defined by either set of criteria exhibited a significantly superior OS compared to the NOS group (IPLc vs. NOSc: HR 0.198, P = 0.008; IPLk vs. NOSk: HR 0.359, P = 0.038); however, the protective effect was more pronounced (lower HR) when stratified by the Chinese criteria. Further statistical analysis using the Cox model revealed no significant interaction between elevated IgG and elevated PLT on OS (P = 0.761). In multivariate models controlling for confounding factors, univariate analysis indicated elevated PLT as a significant protective factor (HR 0.318, P = 0.013); after adjusting for elevated IgG, elevated PLT remained an independent prognostic factor for OS (adjusted HR 0.376, P = 0.037). These findings suggest that, in addition to IgG levels, PLT levels hold significant value for patient classification.

Conclusions

Among non-TAFRO iMCD patients, the Chinese criteria, which incorporate the platelet indicator, not only effectively identify the IPL subgroup with a favourable prognosis but also demonstrate superior survival discrimination compared to the established Kojima criteria. This study supports the application of the current Chinese guidelines' IPL diagnostic criteria, rather than  Kojima Criteria,  for defining this patient population.

Yu-han Gao, PhD: No relevant conflicts of interest to declare.